Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study

Abstract Background Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. Methods We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. Results Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. Conclusions Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population.

[1]  C. Howald,et al.  Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Steinacker,et al.  Post-acute sequelae of covid-19 six to 12 months after infection: population based study , 2022, BMJ.

[3]  Christopher J. L. Murray,et al.  Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. , 2022, JAMA.

[4]  James N. Druckman,et al.  Prevalence and Correlates of Long COVID Symptoms Among US Adults , 2022, JAMA network open.

[5]  Sebastian F N Bode,et al.  Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study , 2022, eBioMedicine.

[6]  L. Borrell,et al.  The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic , 2022, medRxiv.

[7]  R. Cox,et al.  Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[8]  Juarez Antônio Simões Quaresma,et al.  Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction , 2022, JAMA network open.

[9]  P. Heuschmann,et al.  Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study , 2022, eClinicalMedicine.

[10]  Y. Nakagama,et al.  Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies , 2022, Microbiology spectrum.

[11]  D. Needham,et al.  Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID) , 2022, BMC Medicine.

[12]  M. Rescigno,et al.  Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. , 2022, JAMA.

[13]  Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19 , 2022, The Journal of Emergency Medicine.

[14]  H. Goossens,et al.  Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up , 2022, BMJ Open.

[15]  P. Weihe,et al.  Long COVID in the Long Run—23-Month Follow-up Study of Persistent Symptoms , 2022, Open forum infectious diseases.

[16]  C. Steves,et al.  Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 , 2022, The Lancet.

[17]  Z. Al-Aly,et al.  Long COVID after breakthrough SARS-CoV-2 infection , 2022, Nature Medicine.

[18]  N. Ohmagari,et al.  Post COVID-19 condition of the Omicron variant of SARS-CoV-2 , 2022, Journal of Infection and Chemotherapy.

[19]  A. Iwasaki,et al.  Unexplained post-acute infection syndromes , 2022, Nature Medicine.

[20]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[21]  L. Risch,et al.  Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort , 2021, medRxiv.

[22]  J. Geddes,et al.  Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.

[23]  U. Merle,et al.  Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Michelle A. Williams,et al.  Confronting Our Next National Health Disaster - Long-Haul Covid. , 2021, The New England journal of medicine.

[25]  S. Ladhani,et al.  Causation or confounding: why controls are critical for characterizing long COVID , 2021, Nature Medicine.

[26]  L. Risch,et al.  Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study , 2021, BMC Medicine.

[27]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[28]  P. Findeisen,et al.  Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay , 2021, Journal of Virological Methods.

[29]  F. Pitta,et al.  Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19 , 2021, Health and Quality of Life Outcomes.

[30]  L. Risch,et al.  Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study , 2020, Clinical Microbiology and Infection.

[31]  M. Endres,et al.  The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19 , 2020, European Respiratory Journal.

[32]  P. Magnus,et al.  Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. , 2015, Vaccine.

[33]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[34]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[35]  Y. Benyamini,et al.  Self-rated health and mortality: a review of twenty-seven community studies. , 1997, Journal of health and social behavior.

[36]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[37]  P. White,et al.  Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. , 2006, QJM : monthly journal of the Association of Physicians.